Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Monogram Orthopaedics Inc ( (MGRM) ) has provided an update.
On April 29, 2025, Monogram Technologies Inc. announced it received regulatory approval from India’s Central Drugs Standard Control Organization to conduct clinical trials for its mBôs TKA system. This approval marks a significant milestone for Monogram, as it collaborates with Shalby Hospitals to evaluate the safety and effectiveness of its system in a 102-patient trial. The initiative is expected to enhance Monogram’s industry positioning by demonstrating the system’s performance in real surgical settings, potentially advancing orthopedic innovation globally.
Spark’s Take on MGRM Stock
According to Spark, TipRanks’ AI Analyst, MGRM is a Neutral.
Monogram Orthopaedics Inc. has strengths in recent FDA approval and technological advancements, which are key positive drivers. However, financial instability, regulatory uncertainties, and negative profitability weigh heavily on the overall score. While technical indicators show upward momentum, the high RSI indicates potential risk of a pullback. Valuation metrics are weak due to the lack of profitability and dividends.
To see Spark’s full report on MGRM stock, click here.
More about Monogram Orthopaedics Inc
Monogram Technologies Inc. is an AI-driven robotics company focused on orthopedic surgery, aiming to improve human health through patient-optimized orthopedic implants. The company combines 3D printing, advanced machine vision, AI, and next-generation robotics to develop precision robotic surgical systems and related products.
YTD Price Performance: 24.79%
Average Trading Volume: 666,325
Technical Sentiment Signal: Strong Sell
Learn more about MGRM stock on TipRanks’ Stock Analysis page.